The Group's principal activities are the research and development of new drugs, sales of pharmaceuticals and process development and manufacturing of new protein based drugs. The Group conducts research and develops pharmaceuticals both for common diseases and conditions that affect smaller patient populations. The Group also develops drugs for the treatment of obesity, diabetes, inflammation, blood diseases and a number of well defined niche indications. The Group has operations in England, the USA and Europe.
Alacra Alerts:
Receive alerts on the latest reports on Biovitrum AB
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
